サマリー

中東およびアフリカの非ホジキンリンパ腫診断市場は、2023年から2030年の予測期間に6.3%の大幅なCAGRを記録すると予測される。この新しい市場レポートは、歴史的年2021年のデータを含み、計算の基準年は2022年、予測期間は2023年から2030年です。

市場細分化：
中東およびアフリカの非ホジキンリンパ腫診断市場：検査タイプ別（画像診断、生検、免疫組織化学、バイオマーカー検査、遺伝子検査、細胞遺伝学、腰椎穿刺（脊髄穿刺）、血液検査、細胞化学）、癌病期別（ステージIV、ステージIII、ステージII、ステージI、ステージ0）、腫瘍タイプ（進行性リンパ腫、低悪性度リンパ腫）、製品（機器ベース製品、プラットフォームベース製品、キットおよび試薬、その他消耗品）、技術（蛍光in situハイブリダイゼーション、次世代シーケンシング、フルオイムノアッセイ、比較ゲノムハイブリダイゼーション、免疫組織化学、その他）、用途（スクリーニング、診断・予測、予後予測、研究）、エンドユーザー（病院、診断センター、がん研究センター、学術機関、外来手術センター、その他）、流通チャネル（直接入札、小売販売、その他）、国（南アフリカ、サウジアラビア、アラブ首長国連邦、エジプト、イスラエル、中東およびアフリカのその他） 産業動向と2030年までの予測
中東・アフリカの非ホジキンリンパ腫診断市場の成長に寄与している主な要因には、以下のようなものがある：
- 非ホジキンリンパ腫有病率の増加
- 非ホジキンリンパ腫の診断における人工知能の進歩
市場プレイヤー

中東・アフリカの非ホジキンリンパ腫診断市場で事業を展開している主な企業は以下の通り：

- キャノンメディカルシステムズ株式会社
- Koninklijke Philips N.V.
- シーメンスヘルスケアGmbH
- ダナハー
- バイオ・ラッド・ラボラトリーズ・インク
- ゼネラル・エレクトリック社
- シスメックス株式会社
- グレイル
- F.ホフマン・ラ・ロシュ
- ノイソフトコーポレーション
- アジレント・テクノロジー株式会社
- ネオジェノミクス・ラボラトリーズ
- ホロジック社
- インテグレーテッドDNAテクノロジー社
- セントジェン社
- メリット・メディカル・システムズ
- インビタエ・コーポレーション
- パーキンエルマー社
- QIAGEN
- GeneDx, LLC

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 83
1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 83
1.4 LIMITATIONS 85
1.5 MARKETS COVERED 86
2 MARKET SEGMENTATION 89
2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 CURRENCY AND PRICING 91
2.5 DBMR TRIPOD DATA VALIDATION MODEL 92
2.6 MULTIVARIATE MODELLING 95
2.7 PRODUCT TYPE LIFELINE CURVE 95
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
2.9 DBMR MARKET POSITION GRID 97
2.10 MARKET APPLICATION COVERAGE GRID 98
2.11 VENDOR SHARE ANALYSIS 99
2.12 SECONDARY SOURCES 100
2.13 ASSUMPTIONS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 104
4.1 PESTEL ANALYSIS 105
4.2 PORTER'S 5 FORCES 106
5 INDUSTRY INSIGHTS 107
6 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 108
7 MARKET OVERVIEW 110
7.1 DRIVERS 112
7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 112
7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 112
7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 112
7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 113
7.2 RESTRAINTS 113
7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 113
7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 114
7.3 OPPORTUNITIES 115
7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 115
7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 115
7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 115
7.4 CHALLENGES 116
7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 116
7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 116
7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 117
8 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 118
8.1 OVERVIEW 119
8.2 IMAGING 122
8.2.1 COMPUTED TOMOGRAPHY (CT) 123
8.2.2 CHEST X-RAY 123
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 123
8.2.4 ULTRASOUND 123
8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 123
8.3 BIOPSY 123
8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 124
8.3.2 CORE NEEDLE BIOPSY 124
8.4 IMMUNOHISTOCHEMISTRY 124
8.5 BIOMARKER TEST 125
8.5.1 BETA 2-M 126
8.5.2 LDH 126
8.5.3 CA-125 126
8.5.4 TP53 126
8.5.5 NPM1 127
8.5.6 OTHERS 127
8.6 GENETIC TEST 127
8.7 CYTOGENETICS 127
8.8 LUMBAR PUNCTURE (SPINAL TAP) 128
8.9 BLOOD TEST 129
8.10 CYTOCHEMISTRY 129
8.11 OTHERS 130
9 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 131
9.1 OVERVIEW 132
9.2 AGGRESSIVE LYMPHOMAS 134
9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 135
9.2.1.1 INSTRUMENT BASED PRODUCTS 136
9.2.1.2 PLATFORM BASED PRODUCTS 136
9.2.1.3 KITS AND REAGENTS 136
9.2.1.4 OTHER CONSUMABLES 136
9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 136
9.2.2.1 INSTRUMENT BASED PRODUCTS 137
9.2.2.2 PLATFORM BASED PRODUCTS 137
9.2.2.3 KITS AND REAGENTS 137
9.2.2.4 OTHER CONSUMABLES 137
9.2.3 MANTLE CELL LYMPHOMA 137
9.2.3.1 INSTRUMENT BASED PRODUCTS 138
9.2.3.2 PLATFORM BASED PRODUCTS 138
9.2.3.3 KITS AND REAGENTS 138
9.2.3.4 OTHER CONSUMABLES 138
9.2.4 PERIPHERAL T-CELL LYMPHOMA 138
9.2.4.1 INSTRUMENT BASED PRODUCTS 139
9.2.4.2 PLATFORM BASED PRODUCTS 139
9.2.4.3 KITS AND REAGENTS 139
9.2.4.4 OTHER CONSUMABLES 139
9.2.5 LYMPHOBLASTIC LYMPHOMA 139
9.2.5.1 INSTRUMENT BASED PRODUCTS 140
9.2.5.2 PLATFORM BASED PRODUCTS 140
9.2.5.3 KITS AND REAGENTS 140
9.2.5.4 OTHER CONSUMABLES 140
9.2.6 BURKITT LYMPHOMA 140
9.2.6.1 INSTRUMENT BASED PRODUCTS 141
9.2.6.2 PLATFORM BASED PRODUCTS 141
9.2.6.3 KITS AND REAGENTS 141
9.2.6.4 OTHER CONSUMABLES 141
9.3 INDOLENT LYMPHOMAS 141
9.3.1 FOLLICULAR LYMPHOMA 142
9.3.1.1 INSTRUMENT BASED PRODUCTS 143
9.3.1.2 PLATFORM BASED PRODUCTS 143
9.3.1.3 KITS AND REAGENTS 143
9.3.1.4 OTHER CONSUMABLES 143
9.3.2 CUTANEOUS T-CELL LYMPHOMA 143
9.3.2.1 INSTRUMENT BASED PRODUCTS 144
9.3.2.2 PLATFORM BASED PRODUCTS 144
9.3.2.3 KITS AND REAGENTS 144
9.3.2.4 OTHER CONSUMABLES 144
9.3.3 MARGINAL ZONE B CELL LYMPHOMA 144
9.3.3.1 INSTRUMENT BASED PRODUCTS 145
9.3.3.2 PLATFORM BASED PRODUCTS 145
9.3.3.3 KITS AND REAGENTS 145
9.3.3.4 OTHER CONSUMABLES 145
9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 145
9.3.4.1 INSTRUMENT BASED PRODUCTS 146
9.3.4.2 PLATFORM BASED PRODUCTS 146
9.3.4.3 KITS AND REAGENTS 146
9.3.4.4 OTHER CONSUMABLES 146
9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 146
9.3.5.1 INSTRUMENT BASED PRODUCTS 147
9.3.5.2 PLATFORM BASED PRODUCTS 147
9.3.5.3 KITS AND REAGENTS 147
9.3.5.4 OTHER CONSUMABLES 147
10 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 148
10.1 OVERVIEW 149
10.2 SCREENING 151
10.2.1 INSTRUMENT BASED PRODUCTS 152
10.2.2 PLATFORM BASED PRODUCTS 152
10.2.3 KITS AND REAGENTS 153
10.2.4 OTHER CONSUMABLES 153
10.3 DIAGNOSTIC AND PREDICTIVE 153
10.3.1 INSTRUMENT BASED PRODUCTS 154
10.3.2 PLATFORM BASED PRODUCTS 154
10.3.3 KITS AND REAGENTS 154
10.3.4 OTHER CONSUMABLES 154
10.4 PROGNOSTIC 154
10.4.1 INSTRUMENT BASED PRODUCTS 155
10.4.2 PLATFORM BASED PRODUCTS 155
10.4.3 KITS AND REAGENTS 155
10.4.4 OTHER CONSUMABLES 156
10.5 RESEARCH 156
10.5.1 INSTRUMENT BASED PRODUCTS 157
10.5.2 PLATFORM BASED PRODUCTS 157
10.5.3 KITS AND REAGENTS 157
10.5.4 OTHER CONSUMABLES 157
11 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 158
11.1 OVERVIEW 159
11.2 STAGE IV 161
11.3 STAGE I 162
11.4 STAGE III 163
11.5 STAGE II 164
11.6 STAGE 0 165
12 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 166
12.1 OVERVIEW 167
12.2 FLUORESCENT IN SITU HYBRIDIZATION 169
12.3 NEXT GENERATION SEQUENCING 170
12.4 FLUORIMMUNOASSAY 171
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 172
12.6 IMMUNOHISTOLOCHEMICAL 172
12.7 OTHER 173
13 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 174
13.1 OVERVIEW 175
13.2 INSTRUMENT BASED PRODUCTS 177
13.2.1 IMAGING 178
13.2.2 BIOPSY 178
13.3 PLATFORM BASED PRODUCTS 179
13.3.1 NEXT-GENERATION SEQUENCING 180
13.3.2 MICROARRAYS 180
13.3.3 PCR 180
13.3.4 OTHERS 180
13.4 KITS AND REAGENTS 180
13.4.1 NON-HODGKIN LYMPHOMA PANELS 181
13.4.2 IMMUNOHISTOCHEMISTRY STAINS 181
13.4.3 OTHERS 181
13.5 OTHER CONSUMABLES 182
14 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 183
14.1 OVERVIEW 184
14.2 HOSPITALS 186
14.3 DIAGNOSTIC CENTERS 187
14.4 CANCER RESEARCH CENTERS 188
14.5 ACADEMIC INSTITUTES 189
14.6 AMBULATORY SURGICAL CENTERS 189
14.7 OTHERS 190
15 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 191
15.1 OVERVIEW 192
15.2 DIRECT TENDER 194
15.3 RETAIL SALES 195
15.4 OTHERS 196
16 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 197
16.1 MIDDLE EAST AND AFRICA 198
16.1.1 SOUTH AFRICA 216
16.1.2 SAUDI ARABIA 229
16.1.3 U.A.E. 242
16.1.4 EGYPT 255
16.1.5 ISRAEL 269
16.1.6 REST OF MIDDLE EAST AND AFRICA 283
17 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 284
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 284
18 SWOT ANALYSIS 285
19 MIDDLE EAST & AFRICA NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 286
19.1 CANON MEDICAL SYSTEMS CORPORATION 286
19.1.1 COMPANY SNAPSHOT 286
19.1.2 REVENUE ANALYSIS 286
19.1.3 COMPANY SHARE ANALYSIS 287
19.1.4 PRODUCT PORTFOLIO 287
19.1.5 RECENT DEVELOPMENT 287
19.2 KONINKLIJKE PHILIPS N.V. 288
19.2.1 COMPANY SNAPSHOT 288
19.2.2 REVENUE ANALYSIS 288
19.2.3 COMPANY SHARE ANALYSIS 289
19.2.4 PRODUCT PORTFOLIO 289
19.2.5 RECENT DEVELOPMENTS 289
19.3 SIEMENS HEALTHCARE GMBH 290
19.3.1 COMPANY SNAPSHOT 290
19.3.2 REVENUE ANALYSIS 290
19.3.3 COMPANY SHARE ANALYSIS 291
19.3.4 PRODUCT PORTFOLIO 291
19.3.5 RECENT DEVELOPMENT 292
19.4 DANAHER. 293
19.4.1 COMPANY SNAPSHOT 293
19.4.2 REVENUE ANALYSIS 293
19.4.3 COMPANY SHARE ANALYSIS 294
19.4.4 PRODUCT PORTFOLIO 294
19.4.5 RECENT DEVELOPMENTS 295
19.5 BIO-RAD LABORATORIES, INC. 296
19.5.1 COMPANY SNAPSHOT 296
19.5.2 REVENUE ANALYSIS 296
19.5.3 COMPANY SHARE ANALYSIS 297
19.5.4 PRODUCT PORTFOLIO 297
19.5.5 RECENT DEVELOPMENT 297
19.6 AGILENT TECHNOLOGIES, INC. 298
19.6.1 COMPANY PROFILE 298
19.6.2 REVENUE ANALYSIS 298
19.6.3 PRODUCT PORTFOLIO 299
19.6.4 RECENT DEVELOPMENT 299
19.7 CENTOGENE N.V. 300
19.7.1 COMPANY SNAPSHOT 300
19.7.2 PRODUCT PORTFOLIO 300
19.7.3 RECENT DEVELOPMENT 300
19.8 F. HOFFMANN- LA ROCHE LTD 301
19.8.1 COMPANY SNAPSHOT 301
19.8.2 REVENUE ANALYSIS 301
19.8.3 PRODUCT PORTFOLIO 302
19.8.4 RECENT DEVELOPMENTS 302
19.9 GENERAL ELECTRIC COMPANY 303
19.9.1 COMPANY SNAPSHOT 303
19.9.2 REVENUE ANALYSIS 303
19.9.3 PRODUCT PORTFOLIO 304
19.9.4 RECENT DEVELOPMENTS 304